Compare Plby Group Inc (PLBY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Plby Group Inc trades at $1.28 (market cap $143.34M), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 853.4× Plby Group Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| PLBY | VRTX | |
|---|---|---|
Market Cap | $143.34M | $122.33B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $529.59 |
52-Week Low | $1.11 | $366.54 |
Enterprise Value | $291.14M | $117.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.23, up 5.13% today, amid a bearish technical signal. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable. Recent developments include inclusion in the Russell 2000 and 3000 indices and a major share repurchase. Analyst consensus is strongly bullish with 75% buy ratings, reflecting optimism around the company's strategic focus on licensing, media, and experiences.
The outlook for PLBY hinges on sustaining its operational turnaround and achieving profitability. Key opportunities include brand monetization and cost management, while risks involve high debt levels and competitive pressures. Investors should weigh the strong analyst support against the company's historical losses and current negative equity position.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
